Guoxia Technology Co., Ltd. (“Guoxia Tech”) announced that all three special resolutions tabled at its Extraordinary General Meeting (EGM) held on 12 October 2026 were passed with near-unanimous support, clearing the way for a new share award scheme and amendments to the company’s Articles of Association.
The EGM was validly convened at the company’s headquarters in Wuxi, Jiangsu Province, and chaired by Board Chairman Mr. Feng Lizheng. Shareholders and proxies representing 368.57 million shares—about 71.19 % of the company’s 517.71 million issued shares—participated in the poll.
Key resolutions and voting outcomes: • Adoption of the Share Award Scheme: 99.99 % (368.53 million votes) in favour, 0.01 % (0.04 million) against, 0 % abstained. • Authorisation for the Board to administer the Share Award Scheme, including grant approvals, engagement of professional advisers and execution of related documents: 99.99 % (368.53 million) in favour, 0.01 % (0.04 million) against, 0 % abstained. • Amendments to the Articles of Association: 100.00 % (368.57 million) in favour; no opposing or abstention votes.
As all resolutions secured more than the required two-thirds majority, the Share Award Scheme is now effective, granting the Board broad authority to implement and manage the programme aimed at incentivising eligible participants, supporting business development, and aligning management interests with long-term shareholder value.
The approved amendments to the Articles of Association took effect immediately on 12 October 2026 and have been published on both the Hong Kong Stock Exchange (HKEX) and company websites.
Computershare Hong Kong Investor Services Limited acted as scrutineer for H Share votes, while Commerce & Finance Law Offices oversaw the domestic share count.
Guoxia Tech’s issued share capital comprises 394.69 million H Shares and 123.02 million unlisted domestic shares; the company holds no treasury shares.
The Board currently consists of six executive directors—Mr. Feng Lizheng, Mr. Zhang Xi, Mr. Liu Ziye, Dr. Bai Yang, Mr. Zhu Shuaishuai and Mr. Wang Zhenlin—and three independent non-executive directors—Mr. Qian Kaiming, Dr. Jiang Wei and Ms. Jiang Xingnan.